home / stock / trvn / trvn news

TRVN News and Press, Trevena Inc.

Stock Information
Company Name: Trevena Inc.
Stock Symbol: TRVN
Market: NASDAQ
Website: trevena.com
Menu
TRVN TRVN Quote TRVN Short TRVN News TRVN Articles TRVN Message Board
Get TRVN Alerts

News, Short Squeeze, Breakout and More Instantly...
TRVN - US Companies Moving the Markets, Morning edition
Thu, Jun 20, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRVN - Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...

TRVN - Earnings week ahead: NVIDIA, Target, Zoom Video, Snowflake and more

2024-05-19 08:02:00 ET Retailers will also be in the spotlight, with updates anticipated from Target ( NYSE: TGT ), Lowe's ( LOW ), Macy’s ( M ), Ross Stores ( ROST ), TJX Companies ( TJX ), Ralph Lauren ( RL ) and Urban Outfitters ( URBN ).... R...

TRVN - Trevena GAAP EPS of -$0.36 beats by $0.11

2024-05-15 07:52:23 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena Read the full article on Seeking Alpha For further details see: Trevena GAAP EPS of -$0.36...
TRVN - Trevena Reports First Quarter 2024 Results and Provides Business Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- &#x...

TRVN - Market Outperform Recommendation Issued On TRVN By JMP Securities

2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...

TRVN - Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...
TRVN - Trevena files to sell 2.78M shares for holders

2024-01-10 16:41:39 ET More on Trevena Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript Trevena announces private placement and warrant exercise Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial informa...

TRVN - Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“ Trevena ” or the “ Company ”) ( Nasdaq: TRVN ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (C...

TRVN - Trevena announces private placement and warrant exercise

2023-12-27 09:21:21 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena announces private placement and warrant exercise
Next 10